Singapore, Feb. 3 -- AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with China-based CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.

Under this agreement, the companies will initially progress four programmes, which utilise CSPC's advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.

AstraZeneca will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I and th...